HKU and CEPI extend partnership to develop COVID-19 nasal spray
- hkubio2021
- Mar 19, 2021
- 1 min read
In response to the ongoing pandemic of COVID-19, the University of Hong Kong (HKU) has extended its collaboration with the Coalition for Epidemic Preparedness Innovations (CEPI) to evaluate a nasal spray COVID-19 vaccine made with live attenuated influenza viral vector. The effort is led by the State Key Laboratory for Emerging Infectious Diseases (SKL) at HKU.
